Taken together, while conventional amyloid and tau pathology are valuable as AD diagnosis biomarkers, our results suggest that plasma NFL and GFAP may be useful as prognosis biomarkers for cognitive impairment. The gene discussed is NEFL; the disease is amyloidosis.